Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
IDEXX LABORATORIES INC (IDXX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
8-K
| Quarterly results |
| 05/19/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/02/2023 |
8-K
| Quarterly results |
| 02/06/2023 |
8-K
| Quarterly results |
| 11/01/2022 |
8-K
| Quarterly results |
| 10/21/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Quarterly results |
| 02/02/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 12/09/2021 |
8-K
| Quarterly results |
| 11/02/2021 |
8-K
| Quarterly results |
| 07/30/2021 |
8-K
| Quarterly results |
| 05/18/2021 |
8-K
| Quarterly results |
| 05/04/2021 |
8-K
| Quarterly results |
| 02/10/2021 |
8-K
| Quarterly results |
| 02/02/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/29/2020 |
8-K
| Quarterly results |
| 07/31/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/30/2020 |
8-K
| Quarterly results |
| 04/16/2020 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Amendment to Amended and Restated Multi-Currency Note Purchase and Private Shelf Agreement, among the Company, as issuer, each of the Subsidiary Guarantors (as defined therein), Prudential and each of the holders of the Notes (as defined therein)",
"Second Amendment to Amended and Restated Multi-Currency Note Purchase and Private Shelf Agreement, among the Company, as issuer, each of the Subsidiary Guarantors (as defined therein), Prudential and each of the holders of the Notes (as defined therein)",
"Amendment to Note Purchase Agreement, among the Company, as issuer, New York Life Insurance Company, New York Life Insurance and Annuity Corporation and New York Life Insurance and Annuity Corporation Institutionally Owned Life Insurance Separate Account (BOLI 30C), as purchasers",
"Amendment to Note Purchase Agreement, among the Company, as issuer, New York Life Insurance Company, New York Life Insurance and Annuity Corporation and New York Life Insurance and Annuity Corporation Institutionally Owned Life Insurance Separate Account (BOLI 30C), as purchasers",
"Third Amended and Restated Credit Agreement, among the Company, IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX Europe B.V., and IDEXX Holding B.V., as borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and the other parties thereto" |
|
| 04/08/2020 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ... |
| 03/27/2020 |
8-K
| Quarterly results |
| 01/31/2020 |
8-K
| Quarterly results |
| 10/31/2019 |
8-K
| Quarterly results |
| 10/24/2019 |
8-K
| Quarterly results |
| 08/05/2019 |
8-K
| Quarterly results |
| 08/01/2019 |
8-K
| Quarterly results|
Docs:
|
"IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, Aug. 1, 2019 /PRNewswire/ -- Reports revenue growth of 7% on a reported basis and 9% on an organic basis, driven by Companion Animal Group Diagnostics recurring revenue growth of 9% reported and 11% organic Delivers EPS of $1.43, representing 16% growth on a reported basis and 19% on a comparable constant currency basis, reflecting continued strong CAG Diagnostics recurring revenue growth and operating margin gains Refines 2019 revenue guidance to $2,380 million - $2,410 million, reflecting updated expectations for reported revenue growth of 7.5% - 9% and organic revenue growth of 9.5% - 10.5%, supported by CAG Diagnostics recurring reported revenue growth of 9% - 10.5% and consistent expectations for organic revenue gro..." |
|
| 07/24/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
|
|
|